By demonstrating that Tau reduction prevents autism-like phenotypes possibly through modulating the P38/MAPK signaling in Fmr1 KO mice, this study provides strong evidence that Tau is a new target for FXS therapeutics. The gene discussed is MAPT; the disease is fragile X syndrome.